

Review questions

What is the most appropriate healthcare setting to initiate pre-therapeutic tests (HBeAg, quantitative HBsAg, quantitative HBV DNA, anti HCV, anti HDV, anti HIV) in people who are HBsAg positive?

What are the thresholds (e.g. HBV DNA and ALT levels) for referral to specialist services after initial diagnosis and pre-therapeutic tests of CHB?

What is the diagnostic test accuracy of non-invasive methods (e.g. transient elastography, serum fibrosis markers, aspartate aminotransferase / platelet ration index, magnetic resonance spectroscopy) to assess the severity of necro-inflammatory activity and liver fibrosis?

Does genotype testing enable better decisions on which antiviral treatment to offer and is it cost effective?

In people with CHB, what is the clinical and cost effectiveness of pharmacological monotherapies and combinations in achieving remission of the activity of CHB?

In people with CHB, what is the clinical and cost-effectiveness of sequential drug therapy (add-on or switching monotherapies) in achieving remission of the activity of CHB?

In chronic hepatitis B infected people with advanced cirrhosis, including those with liver decompensation, what is the clinical and cost effectiveness of antiviral treatment to prevent recurrent reactivation and liver transplantation?

How frequently should monitoring tests be done to ascertain virological, serological and biochemical response and resolution of fibrosis (HBeAg and antibody, HBsAg and antibody and transient elastography) and resistance (HBV DNA) in people with chronic hepatitis B?

In people who are immunocompromised, what is the clinical and cost effectiveness of prophylactic treatment in reducing risk of hepatitis B virus reactivation and severity of flares?

When and how frequently should surveillance testing be offered to detect early hepatocellular carcinoma in people with chronic hepatitis B?

In pregnant/lactating women with chronic hepatitis B what is the clinical and cost-effectiveness of pharmacological or anti-viral therapy in order to reduce risk of vertical transmission from mother to infant?

What are the information needs of patients with CHB and their carers?